NeuroVive is in the planning stage for commercialization of CicloMulsion, currently in a Phase III study to determine the drug's effectiveness in reducing cardiac damage following stenting in heart attack patients. The companies recently completed a one-year regulatory consulting project with ParagonRx, inVentiv's risk mitigation service. inVentiv will now provide market assessment services through its consulting arm, Campbell Alliance.
"We're big enough to step in and provide NeuroVive with virtually any service they require to develop and commercialize their compound, and we're flexible enough to align with whatever they need to achieve their objectives," said Dan Feldman, president of inVentiv Health Europe. "Pharmaceutical companies face a far more challenging market environment than ever before. Today's market requires innovative strategic partnerships. inVentiv Health was created to provide this new model for the new marketplace."
"We are very pleased to extend the collaboration with inVentiv Health, an important step in preparing the market for launch of CicloMulsion in Europe and, later, in the U.S.," said Mikael Bronnegard, chief executive officer of NeuroVive. "inVentiv Health's commercial services will provide a valuable platform for optimal market penetration at later stages and when approaching the launch and marketing of the product."